Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer.

Current oncology (Toronto, Ont.) - 24 Jun 2026

Chen Chian-Wei, Tsai Jui-Hung, Tsai Sheng-Han, Chen Li-Jun, Yang Szu-Chun

Abstract excerpt

Patients with BRAFV600E-mutated metastatic lung cancer benefit from both BRAF plus MEK inhibitors and immune checkpoint inhibitor (ICI)-chemotherapy. This study evaluated the cost-effectiveness of first-line ICI-chemotherapy compared with BRAF plus MEK inhibitors in these patients. This economic analysis, with a 15-year time horizon and an annual 3% discount, was conducted from the perspective of the healthcare...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 42505186
DOI: 10.3390/curroncol33070384
PMCID: PMC13408117

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer.PMID 42505186Read ↗

First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness AnalysisSemantic proximity Read ↗

First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness AnalysisSemantic proximity Read ↗

Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.Semantic proximity Read ↗

Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In ChinaSemantic proximity Read ↗

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review.Semantic proximity Read ↗

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.Semantic proximity Read ↗

Cost-effectiveness analysis of first-line gefitinib plus anlotinib treatment for patients with stage IIIB-IV EGFR-mutated NSCLC in China.Semantic proximity Read ↗

Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI-resistant, EGFR-mutated advanced NSCLC in China.Semantic proximity Read ↗

Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.Semantic proximity Read ↗

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.